Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$41.57 USD
-0.88 (-2.07%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $41.61 +0.04 (0.10%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AMPH 41.57 -0.88(-2.07%)
Will AMPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMPH
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View
UnitedHealth Group (UNH) Q2 Earnings Beat on Strong Optum Unit
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Amphastar (AMPH) is Poised to Beat Earnings Estimates Again
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
Implied Volatility Surging for Amphastar (AMPH) Stock Options
Other News for AMPH
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
Insider Sale: CFO, EVP & Treasurer William Peters Sells Shares of Amphastar Pharmaceuticals ...
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Verona Pharma (VRNA) and Henry Schein (HSIC)
Piper Sandler Keeps Their Buy Rating on Amphastar Pharmaceuticals (AMPH)
Amphastar management to meet with Piper Sandler